What does L stand for?

The material is presented in sections on chiral monodentate phosphorous ligands, chiral bidentate phosphorous ligand diphosphines, mixed P-ligands, hybrid monophosphorous ligands, chiral polyphosphorous ligands, dynamic processes of P-ligands and their complexes, chiral ligands for reactions in alternative media and concepts of heterogenization, P-ligands bound to chiral biomolecules, mixtures of monodentate P-ligands in stereo- and regioselective transition metal catalysis, general methods for the synthesis of chiral trivalent phosphorous compounds, controlling regio- and stereochemistry in metal-catalyzed and metal-mediated reactions with the aid of substrate-bound reagent-directing phosphine groups, characterization of P-ligands and metal complexes, and industrial aspects.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has received $2 million in milestone payments from N.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has amended its license agreement with Exelixis, Inc.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that a subsidiary of Ligand has entered into an exclusive license agreement with ParinGenix Inc.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reported a correction to its earnings release issued on May 6, 2009 relating to a milestone earned from Pfizer, Inc.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (the "Company" or "Ligand") and The Rockefeller University ("Rockefeller") have entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement").

Symphogen Adds Receptor's Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody Portfolio-- --Both Technology Platforms Explicitly Target Disease Complexity-- COPENHAGEN, Denmark & PALO ALTO, Calif.

SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that it has entered into an exclusive, worldwide license agreement with GlaxoSmithKline ("GSK") (NYSE:GSK) under which Ligand has licensed worldwide exclusive rights to Ligand's LGD-4665 product candidate and its other thrombopoietin (TPO)-related molecules to GSK.